Innoviva reported an increase in global net sales for RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA® in the first quarter of 2020.
Global net sales of RELVAR®/BREO® ELLIPTA® increased 31% versus the first quarter of 2019.
U.S. net sales of RELVAR®/BREO® ELLIPTA® increased by 47% due to increased pricing discounts offset by a one-time significant positive prior period rebate adjustment and continued volume growth.
ANORO® ELLIPTA® global net sales increased 15% in the first quarter of 2020.
TRELEGY® ELLIPTA global net sales were $248.2 million.
The impact of the COVID-19 pandemic on the global sales of our three collaboration products is uncertain. First quarter sales levels may have benefited from unspecified levels of increased patient inventory stocking. The significant RELVAR®/BREO® ELLIPTA® positive prior period rebate adjustment that occurred during the first quarter is not likely to recur in future quarters.
Analyze how earnings announcements historically affect stock price performance